帕立骨化醇与缓释骨化二醇治疗非透析慢性肾脏病继发性甲状旁腺功能亢进:一项网状Meta分析结果
本网状Meta分析纳入9项随机对照试验共1426例非透析慢性肾脏病患者,比较缓释骨化二醇与帕立骨化醇对甲状旁腺激素、钙和磷的影响。未发现头对头试验;两者降低甲状旁腺激素无统计学显著差异,帕立骨化醇较缓释骨化二醇使血钙升高0.2 mg/dL(95%CI,-0.37至-0.05 mg/dL),对血磷影响无差异。
要点
- 缓释骨化二醇与帕立骨化醇降低甲状旁腺激素水平相当,无统计学显著差异。
- 帕立骨化醇较缓释骨化二醇使血钙升高0.2 mg/dL(95%CI,-0.37至-0.05 mg/dL)。
- 两者对血磷的影响无差异,未发现头对头试验。
核心结论
- 本网状Meta分析显示缓释骨化二醇降低甲状旁腺激素水平与帕立骨化醇相当。
- 缓释骨化二醇可避免血清钙的潜在临床相关升高,为非透析慢性肾脏病继发性甲状旁腺功能亢进提供有效且耐受良好的治疗选择。
研究设计与样本
- 在PubMed进行系统文献检索以识别随机对照试验,采用GRADE方法进行质量评价。
- 采用频率学框架下的随机效应模型比较缓释骨化二醇与帕立骨化醇的效果。
- 共纳入9项随机对照试验、1426例患者,因部分纳入研究未报告结局而在2个重叠网络上进行分析。
- 未识别到头对头试验。
主要发现
- 帕立骨化醇与缓释骨化二醇在降低甲状旁腺激素方面无统计学显著差异。
- 帕立骨化醇较缓释骨化二醇使血钙升高0.2 mg/dL(95%CI,-0.37至-0.05 mg/dL)。
- 两者对血磷的影响无差异。
临床怎么用
- 原文结论认为缓释骨化二醇降低甲状旁腺激素与帕立骨化醇相当,并可避免血清钙的潜在临床相关升高,为非透析慢性肾脏病继发性甲状旁腺功能亢进提供有效且耐受良好的治疗选择。
局限性
- 因部分纳入研究未报告结局,分析在2个重叠网络上进行。
- 未识别到头对头试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD) affecting mineral and bone metabolism and characterized by excessive parathyroid hormone (PTH) production and parathyroid hyperplasia. OBJECTIVE: The objective of this analysis was to compare the efficacy and adverse effects of extended-release calcifediol (ERC) and paricalcitol (PCT) by assessing their effect on the biomarkers PTH, calcium, and phosphate in patients with non-dialysis CKD (ND-CKD). METHODS: A systematic literature research was performed in PubMed to identify randomized control trials (RCTs). Quality assessment was done with the GRADE method. The effects of ERC vs PCT were compared using random effects in a frequentist setting. RESULTS: Nine RCTs comprising 1426 patients were included in the analyses. The analyses were performed on 2 overlapping networks, due to nonreporting of outcomes in some of the included studies. No head-to-head trials were identified. No statistically significant differences in PTH reduction were found between PCT and ERC. Treatment with PCT showed statistically significant increases in calcium compared with ERC (0.2 mg/dL increase; 95% CI, -0.37 to -0.05 mg/dL). No differences in effects on phosphate were observed. CONCLUSION: This network meta-analysis showed that ERC is comparable in lowering PTH levels vs PCT. ERC displayed avoidance of potentially clinically relevant increases in serum calcium, offering an effective and well-tolerated treatment option for the management of SHPT in patients with ND-CKD.
引用
- Franchi M, Gunnarsson J, Gonzales-Parra E, et al. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. J Clin Endocrinol Metab. 2023. PMID: 37235771. doi:10.1210/clinem/dgad289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。